Meta-analysis of risk factors for cutaneous melanoma: II ,
A review of human carcinogens???Part D: radiation, The Lancet Oncology, vol.10, issue.8, pp.751-752, 2009. ,
DOI : 10.1016/S1470-2045(09)70213-X
Le bronzage artificiel: une menace bien réelle, mais évitable, pour la santé publique [Internet], Bulletin Epidémiologique Hebdomadaire, p.2012 ,
Sentinel Lymph Node Biopsy in Melanoma, The Cancer Journal, vol.18, issue.2, pp.185-191 ,
DOI : 10.1097/PPO.0b013e31825046c7
Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma, Cancer, vol.6, issue.11, pp.2647-2652, 2006. ,
DOI : 10.1016/S0039-6060(98)70121-7
Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes, Annals of Surgical Oncology, vol.21, issue.2, pp.119-125, 1998. ,
DOI : 10.1001/archsurg.1992.01420040034005
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma., Journal of Clinical Oncology, vol.16, issue.6, pp.2253-2260, 1998. ,
DOI : 10.1200/JCO.1998.16.6.2253
Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients, Annals of Surgical Oncology, vol.14, issue.3, pp.709-717, 2010. ,
DOI : 10.1001/archsurg.1992.01420040034005
MSLT-II) -Full Text View -ClinicalTrials.gov [Internet] ,
Excision Margins in High-Risk Malignant Melanoma, New England Journal of Medicine, vol.350, issue.8 ,
DOI : 10.1056/NEJMoa030681
Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick), Cancer, vol.97, issue.8, pp.1941-1946, 2003. ,
DOI : 10.1002/cncr.11272
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline, European Journal of Cancer, vol.46, issue.2, pp.270-283, 2010. ,
DOI : 10.1016/j.ejca.2009.10.032
Surgical Margins for Lentigo Maligna and Lentigo Maligna Melanoma, Archives of Dermatology, vol.140, issue.9, pp.1087-1092, 2004. ,
DOI : 10.1001/archderm.140.9.1087
Adjuvant Postoperative Radiotherapy to the Cervical Lymph Nodes in Cutaneous Melanoma: Is There Any Benefit for High-Risk Patients?, Annals of Surgical Oncology, vol.81, issue.11, pp.3022-3027, 2008. ,
DOI : 10.1245/s10434-008-0087-8
Radiation Therapy Field Extent for Adjuvant Treatment of Axillary Metastases From Malignant Melanoma, International Journal of Radiation Oncology*Biology*Physics, vol.73, issue.5, pp.1376-1382, 2009. ,
DOI : 10.1016/j.ijrobp.2008.06.1910
A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma???Trans Tasman Radiation Oncology Group (TROG) Study 96.06, Radiotherapy and Oncology, vol.81, issue.2, pp.136-142, 2006. ,
DOI : 10.1016/j.radonc.2006.10.001
Postoperative radiotherapy for cutaneous melanoma of the head and neck region, International Journal of Radiation Oncology*Biology*Physics, vol.30, issue.4, pp.795-798, 1994. ,
DOI : 10.1016/0360-3016(94)90351-4
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial, The Lancet Oncology, vol.13, issue.6, pp.589-597 ,
DOI : 10.1016/S1470-2045(12)70138-9
Adjuvant radiotherapy for cutaneous melanoma: Comparing hypofractionation to conventional fractionation, International Journal of Radiation Oncology*Biology*Physics, vol.66, issue.4, pp.1051-1055, 2006. ,
DOI : 10.1016/j.ijrobp.2006.05.056
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview, J Exp Clin Cancer Res, vol.19, pp.21-34, 2000. ,
Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study, Journal of Clinical Oncology, vol.22, issue.6, pp.1118-1125, 2004. ,
DOI : 10.1200/JCO.2004.04.165
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma, Journal of Clinical Oncology, vol.18, issue.1, pp.158-166, 2000. ,
DOI : 10.1200/JCO.2000.18.1.158
A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous Melanoma, New England Journal of Medicine, vol.307, issue.15, pp.913-916, 1982. ,
DOI : 10.1056/NEJM198210073071503
DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040, Cancer, vol.20, issue.11, pp.2556-2562, 1981. ,
DOI : 10.1002/1097-0142(19810601)47:11<2556::AID-CNCR2820471107>3.0.CO;2-J
Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG, Journal of Surgical Oncology, vol.1, issue.4, pp.235-238, 1987. ,
DOI : 10.1001/archsurg.1980.01380060021006
Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial, Surgical Clinics of North America, vol.61, issue.6, pp.1267-1277, 1981. ,
DOI : 10.1016/S0039-6109(16)42582-X
Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia, Head & Neck, vol.93, issue.2, pp.267-272, 2008. ,
DOI : 10.1111/j.1440-0960.1997.tb01013.x
Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma, Journal of Clinical Oncology, vol.30, issue.21, pp.2678-2683 ,
DOI : 10.1200/JCO.2011.37.8539
General principles and first clinical trials of therapeutic vaccines against cancer], Bull Cancer, vol.95, pp.327-335, 2008. ,
[Passive immunotherapy of melanoma], Bull Cancer, vol.90, pp.583-586, 2003. ,
Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group, Journal of Clinical Oncology, vol.20, issue.8, pp.2058-2066, 2002. ,
DOI : 10.1200/JCO.2002.08.071
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial, Journal of the American College of Surgeons, vol.187, issue.1, pp.69-77, 1998. ,
DOI : 10.1016/S1072-7515(98)00097-0
Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial, Journal of Clinical Oncology, vol.20, issue.20, pp.4181-4190, 2002. ,
DOI : 10.1200/JCO.2002.12.094
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside., Journal of Clinical Oncology, vol.12, issue.5, pp.1036-1044, 1994. ,
DOI : 10.1200/JCO.1994.12.5.1036
High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801, Journal of Clinical Oncology, vol.19, issue.9, pp.2370-2380, 2001. ,
DOI : 10.1200/JCO.2001.19.9.2370
Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.12, issue.3, pp.1853-1860, 2007. ,
DOI : 10.4049/jimmunol.173.12.7125
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.539-546, 2002. ,
DOI : 10.1007/s00262-002-0315-1
Redefining the role of interferon in the treatment of malignant diseases, European Journal of Cancer, vol.46, issue.2, pp.284-297, 2010. ,
DOI : 10.1016/j.ejca.2009.10.013
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684., Journal of Clinical Oncology, vol.14, issue.1, pp.7-17, 1996. ,
DOI : 10.1200/JCO.1996.14.1.7
Does adjuvant interferon-?? for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials, Cancer Treatment Reviews, vol.29, issue.4, pp.241-252, 2003. ,
DOI : 10.1016/S0305-7372(03)00074-4
Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991, European Journal of Cancer, vol.48, issue.2, pp.218-225 ,
DOI : 10.1016/j.ejca.2011.09.028
Ulcerated Melanoma -Full Text View -ClinicalTrials.gov [Internet] ,
Immunotherapy for Melanoma: Current Status and Perspectives, Journal of Immunotherapy, vol.33, issue.6, pp.570-590, 2010. ,
DOI : 10.1097/CJI.0b013e3181e032e8
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors, Cancer Biotherapy & Radiopharmaceuticals, vol.25, issue.6, pp.601-613, 2010. ,
DOI : 10.1089/cbr.2010.0865
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010. ,
DOI : 10.1056/NEJMoa1003466
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2526, 2011. ,
DOI : 10.1056/NEJMoa1104621
Mechanisms of regulating the Raf kinase family, Cellular Signalling, vol.15, issue.5, pp.463-469, 2003. ,
DOI : 10.1016/S0898-6568(02)00139-0
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011. ,
DOI : 10.1056/NEJMoa1103782
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, p.2012, 2012. ,
DOI : 10.1016/S0140-6736(12)60868-X
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [Internet], The New England Journal of Medicine, p.2012, 2012. ,
Ipilimumab Vemurafenib Combo -Full Text View -ClinicalTrials.gov [Internet], 2012. ,
Randomised trial of interferon ??-2a as adjuvant therapy in resected primary melanoma thicker than 1??5 mm without clinically detectable node metastases, The Lancet, vol.351, issue.9120, pp.1905-1910, 1998. ,
DOI : 10.1016/S0140-6736(97)12445-X
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial, The Lancet, vol.372, issue.9633, pp.117-126, 2008. ,
DOI : 10.1016/S0140-6736(08)61033-8
URL : https://hal.archives-ouvertes.fr/hal-00485095
Diagnosis and management of melanoma with regional lymph node metastases: a population-based study in France, Journal of the European Academy of Dermatology and Venereology, vol.372, issue.Suppl 5, p.201222845015, 2012. ,
DOI : 10.1016/S0140-6736(08)61033-8
Faisabilit?? et tol??rance du traitement adjuvant des m??lanomes par immunoth??rapie selon le protocole de Kirkwood, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.1, pp.50-51, 2005. ,
DOI : 10.1016/S0151-9638(05)79199-7